Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.48 |
| ▸ | DRD2 | P14416 | 9/20 | 0.48 |
| ▸ | HTR2A | P28223 | 6/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796556 | 0.86 | DRD2 (0.53) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL5773463 | 0.85 | KDM4E (0.49) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL5778134 | 0.85 | HTR1A (0.53) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL5775854 | 0.85 | DRD2 (0.54) | HTR1ADRD2HTR2AFAAHDRD3 | |
| SCHEMBL5775488 | 0.83 | DRD2 (0.52) | HTR1ADRD2HTR2ADRD3 | |
| SCHEMBL5777128 | 0.82 | DRD2 (0.53) | HTR1ADRD2HTR2AFAAHDRD3 | |
| SCHEMBL5777048 | 0.82 | DRD2 (0.56) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL5772832 | 0.81 | SIGMAR1 (0.53) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL5772457 | 0.81 | SIGMAR1 (0.52) | HTR1ADRD2HTR2ADRD3HTR7 | |
| SCHEMBL5776684 | 0.79 | SIGMAR1 (0.53) | HTR1ADRD2HTR2ADRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0885883-B1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-6187774-B1 | N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0885883-A1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |